Lead identification of conformationally restricted β-lactam type combretastatin analogues: Synthesis, antiproliferative activity and tubulin targeting effects

Miriam Carr, Lisa M. Greene, Andrew J.S. Knox, David G. Lloyd, Daniela M. Zisterer, Mary J. Meegan

Research output: Contribution to journalArticlepeer-review

76 Citations (Scopus)

Abstract

The synthesis and study of the structure-activity relationships of a series of rigid analogues of combretastatin A-4 are described which contain the 1,4-diaryl-2-azetidinone (β-lactam) ring system in place of the usual ethylene bridge present in the natural combretastatin stilbene products. The 1,4-diaryl-2-azetidinones are unsubstituted at C-3, or contain methyl substituent(s) at C-3. The most potent compounds 12d and 12e display antiproliferative activity at nanomolar concentrations when evaluated against the MCF-7 and MDA-MB-231 human breast carcinoma cell lines. 12d exerts antimitotic effects through an inhibition of tubulin polymerisation and subsequent G2/M arrest of the cell cycle in human MDA-MB-231 breast cancer cells, with similar activity to that of CA-4. These novel β-lactam compounds are identified as potentially useful scaffolds for the further development of antitumour agents which target tubulin.

Original languageEnglish
Pages (from-to)5752-5766
Number of pages15
JournalEuropean Journal of Medicinal Chemistry
Volume45
Issue number12
DOIs
Publication statusPublished - Dec 2010

Keywords

  • β-Lactam
  • 2-Azetidinone
  • Combretastatin A-4 analogues
  • Cytotoxicity
  • Structure-activity
  • Tubulin

Fingerprint

Dive into the research topics of 'Lead identification of conformationally restricted β-lactam type combretastatin analogues: Synthesis, antiproliferative activity and tubulin targeting effects'. Together they form a unique fingerprint.

Cite this